ArticleFrontiers in microbiology2022
New Mutations in
Article in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 19 citations in OpenAlex.
- Saturated fatty acids enhance daptomycin activity in a Fak-dependent manner in enterococci.Microbiology (Reading, England) · 2026Article
- The DUF998 family protein DrmA modulates cationic glycolipid levels and the emergence of high-level daptomycin resistance inbioRxiv : the preprint server for biology · 2026Article
- Culture-enriched metagenomic sequencing reveals within-patient diversity and transmission of vancomycin-resistantMicrobial genomics · 2026Article
- A bacterial-type cardiolipin synthase in Plasmodium spp. supports mitochondrial respiration and is important for liver stage maturation.PLoS pathogens · 2026Article
- Non-susceptibility ofMicrobiology spectrum · 2026Article
- Culture-enriched metagenomic sequencing reveals within-patient diversity and transmission of vancomycin-resistantmedRxiv : the preprint server for health sciences · 2026Article
- A Daptomycin Resistance-Conferring cls1 I269T Mutation in Enterococcus faecium and its Global Prevalence.Current microbiology · 2026Article
- Lipopeptide Engineering: From Natural Origins to Rational Design Against Antimicrobial Resistance.Antibiotics (Basel, Switzerland) · 2026Review
- Article
- Harnessing the Potential of Antibacterial and Antibiofilm Phytochemicals in the Combat Against Superbugs: A One Health Perspective.Antibiotics (Basel, Switzerland) · 2025Review
- Polymeric Anti-Antibiotic Microparticles to Prevent Antibiotic Resistance Evolution.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- A Comprehensive Overview of Antibacterial Agents for Combating Multidrug-Resistant Bacteria: The Current Landscape, Development, Future Opportunities, and Challenges.Antibiotics (Basel, Switzerland) · 2025Review
- Resistance to last-resort antibiotics in enterococci.FEMS microbiology reviews · 2025Review
- Article
- In Vivo-Acquired Resistance to Daptomycin during Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2023Article
- Phylogeny, Virulence, and Antimicrobial Resistance Gene Profiles ofAntibiotics (Basel, Switzerland) · 2023Article
- Genomic characterization of vancomycin-resistantFrontiers in microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Daptomycin (DAP), a last-resort antibiotic for treating Gram-positive bacterial infection, has been widely used in the treatment of vancomycin-resistant enterococci (VRE). Resistance to both daptomycin and vancomycin leads to difficulties in controlling infections of enterococci. A clinical multidrug-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.